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LETTER TO THE EDITOR
Commentary to
‘‘Chromogranin A:
Biological Function and
Clinical Utility in
Neuroendocrine Tumor
Disease’’
TO THE EDITORS:
We read with interest the study by Modlin et al., pub-
lished online on March 9, 2010, and although overall we
found it to be valid,
1 we found an error. We refer to this
assertion in the abstract: ‘‘Serum and plasma measurements
are concordant.’’ This is not true because they differ
markedly. Chromogranin A (CgA) measured in plasma
appears to be far higher than in serum. This is supported by
information provided on the Web site of CIS Bio Interna-
tional (Gif-sur-Yvette, France), the producer of immunora-
diometric assay and enzyme immunoassay kits.
In the Discussion, Modlin et al. are right when they note
that there is strong positive linear relationship between
plasma and serum CgA levels, but this does not mean that
the results are concordant and that the measurements
undertaken in either sample type can be related to the same
cutoff value.
According to the information presented on CIS Bio
International’s Web site, the cutoff value for plasma CgA
is approximately 150 ng/mL, which is approximately 50%
higher than for the serum samples. The same observation
appears in Fig. 1 in the article of Woltering et al.,
2 which
has been cited by Modlin et al. in relation to the discussed
correlation between plasma and serum CgA levels. It is
possible that Modlin et al. did not analyze this ﬁgure
carefully enough; it shows that the serum CgA level of
100 ng/mL corresponds to 150 ng/mL plasma level.
A similar comparison of CgA measurements in serum
and plasma samples obtained contemporaneously from the
same people (volunteers and patients) was performed in
our laboratory, and we can conﬁrm that these differences
are real.
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